Efficacy News and Research

RSS

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

Many parents give young kids medicines that they should not use

Children can get five to 10 colds each year, so it's not surprising that adults often turn to over-the-counter cough and cold medicines to relieve their little ones' symptoms. But a new University of Michigan poll shows that many are giving young kids medicines that they should not use.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

New collaboration to expand vaccine approaches for melanoma

Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro's vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.

22 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Arthritis drug reduces dry eye disease

Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life.

19 Apr 2013

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

Patients from ethnic minority and mixed-racial backgrounds are less likely to receive a lifesaving bone marrow transplant than Caucasian patients with the same disease due to lack of matching donors, according to the National Marrow Donor Program.

19 Apr 2013

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.

19 Apr 2013

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

ADial Pharmaceuticals, LLC, announced today that the U.S. Food and Drug Administration has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder in certain targeted genotypes population only.

19 Apr 2013

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Sinovac Biotech Ltd., a leading provider of vaccines in China, announced today that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C.

19 Apr 2013

Longer looks: The timely trauma response in Boston; Problems with aging doctors; Transplants from donors with HIV

The bombs at the Boston Marathon were designed to maim and kill, and they did. Three people died within the first moments of the blast. More than a hundred and seventy people were injured. They had their limbs blown off, vital arteries severed, bones fractured, flesh torn open by shrapnel or scorched by the blasts' heat. Yet it now appears that every one of the wounded alive when rescuers reached them will survive.

19 Apr 2013

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.

19 Apr 2013

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.

18 Apr 2013

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA.

18 Apr 2013

Efficacy News and Research

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Many parents give young kids medicines that they should not use

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

New collaboration to expand vaccine approaches for melanoma

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Arthritis drug reduces dry eye disease

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Longer looks: The timely trauma response in Boston; Problems with aging doctors; Transplants from donors with HIV

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

New assays are effective in managing patients with influenza virus infection

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News